Climb Bio (CLYM) Net Income (2020 - 2026)
Climb Bio's (CLYM) quarterly Net Income came in at -$46.1 million in Q1 2026, down 116.57% YoY from $278.0 million in Q1 2025, and down 57.73% on a QoQ basis from -$29.2 million in Q4 2025.
Climb Bio (CLYM) Net Income (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Net Income data on file, last reported at -$46.1 million in Q1 2026.
- Quarterly Net Income fell 116.57% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.3 million (down 0.81% YoY) and the FY2025 annual result came in at -$71.3 million, up 30.37% from the prior year.
- Net Income eased to -$46.1 million in Q1 2026, from -$29.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$2.7 million in Q1 2024 to a low of -$57.7 million in Q2 2024.
- A 5-year average of -$19.7 million and a median of -$14.5 million in 2022 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income surged 89.04% — and 2025, when it plunged 676.95%.
- Tracing CLYM's Net Income over 5 years: stood at -$14.5 million in 2022, then sank by 69.94% to -$24.6 million in 2023, then jumped by 64.92% to -$8.6 million in 2024, then plunged by 237.93% to -$29.2 million in 2025, then plunged by 57.73% to -$46.1 million in 2026.
- The last three Net Income figures came in at -$46.1 million (Q1 2026), -$29.2 million (Q4 2025), and -$14.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | -92.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.40 Mn |
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -29.20 Mn |
| Sep 30, 2025 | -14.46 Mn |
| Jun 30, 2025 | -8.54 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -8.64 Mn |
| Sep 30, 2024 | -9.88 Mn |
| Jun 30, 2024 | -57.68 Mn |
| Mar 31, 2024 | -2.74 Mn |
| Dec 31, 2023 | -24.63 Mn |
| Sep 30, 2023 | -5.06 Mn |
| Jun 30, 2023 | -7.84 Mn |
| Mar 31, 2023 | -24.98 Mn |
| Dec 31, 2022 | -14.49 Mn |
| Sep 30, 2022 | -12.65 Mn |
| Jun 30, 2022 | -17.49 Mn |
| Mar 31, 2022 | -29.11 Mn |
| Dec 31, 2021 | -21.40 Mn |
| Sep 30, 2021 | -51.11 Mn |